{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:23:03Z","timestamp":1792891383572,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11606-018-4649-6","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T18:41:59Z","timestamp":1537468919000},"page":"2005-2013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Race and Hepatitis C Care Continuum in an Underserved Birth Cohort"],"prefix":"10.1007","volume":"34","author":[{"given":"Nicole J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"4649_CR1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cid\/ciw111","volume":"62","author":"KN Ly","year":"2016","unstructured":"Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis 2016;62:1287\u20138.","journal-title":"Clin Infect Dis"},{"key":"4649_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2893.2011.01563.x","volume":"19","author":"AC El Khoury","year":"2012","unstructured":"El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012;19:153\u201360.","journal-title":"J Viral Hepat"},{"key":"4649_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/17474124.2015.1001366","volume":"9","author":"AJ van der Meer","year":"2015","unstructured":"van der Meer AJ. Achieving sustained virological response: what\u2019s the impact on further hepatitis C virus-related disease? Expert Rev Gastroenterol Hepatol 2015;9:559\u201366.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4649_CR4","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ van der Meer","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584\u201393.","journal-title":"JAMA"},{"key":"4649_CR5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.cgh.2013.11.032","volume":"12","author":"ZM Younossi","year":"2014","unstructured":"Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014;12:1349\u201359 e13.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4649_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","volume":"156","author":"KN Ly","year":"2012","unstructured":"Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271\u20138.","journal-title":"Ann Intern Med"},{"key":"4649_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.15585\/mmwr.mm6518a3","volume":"65","author":"B Reilley","year":"2016","unstructured":"Reilley B, Leston J, Hariri S, et al. Birth cohort testing for hepatitis C virus - Indian health service 2012-2015. MMWR Morb Mortal Wkly Rep 2016;65:467\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4649_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/cncr.29936","volume":"122","author":"AB Ryerson","year":"2016","unstructured":"Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:1312\u201337.","journal-title":"Cancer"},{"key":"4649_CR9","unstructured":"Testing Recommendations for Hepatitis C Virus Infection. Centers for Disease Control, 2012. Accessed October 11, 2017, at \nhttps:\/\/www.cdc.gov\/hepatitis\/hcv\/guidelinesc.htm"},{"key":"4649_CR10","unstructured":"Final Update Summary: Hepatitis C: Screening. U.S. Preventive Services Task Force, 2013. Accessed October 11, 2017, at \nhttps:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/hepatitis-c-screening\n\n."},{"key":"4649_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11894-014-0381-5","volume":"16","author":"SK Asrani","year":"2014","unstructured":"Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep 2014;16:381.","journal-title":"Curr Gastroenterol Rep"},{"key":"4649_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.26304","volume":"58","author":"P McEwan","year":"2013","unstructured":"McEwan P, Ward T, Yuan Y, Kim R, L\u2019Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013;58:54\u201364.","journal-title":"Hepatology"},{"key":"4649_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","volume":"156","author":"DB Rein","year":"2012","unstructured":"Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012;156:263\u201370.","journal-title":"Ann Intern Med"},{"key":"4649_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7326\/M17-0118","volume":"167","author":"S Kattakuzhy","year":"2017","unstructured":"Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med 2017;167:311\u20138.","journal-title":"Ann Intern Med"},{"key":"4649_CR15","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.cgh.2015.07.015","volume":"13","author":"AJ Muir","year":"2015","unstructured":"Muir AJ, Naggie S. Hepatitis C virus treatment: is it possible to cure all hepatitis c virus patients? Clin Gastroenterol Hepatol 2015;13:2166\u201372.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4649_CR16","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C."},{"key":"4649_CR17","doi-asserted-by":"crossref","unstructured":"Spradling PR, Xing J, Rupp LB, et al. Uptake of and factors associated with direct-acting antiviral therapy among patients in the chronic hepatitis cohort study, 2014 to 2015. J Clin Gastroenterol. 2017.","DOI":"10.1097\/MCG.0000000000000857"},{"issue":"Suppl 4","key":"4649_CR18","doi-asserted-by":"publisher","first-page":"S555","DOI":"10.2105\/AJPH.2014.302090","volume":"104","author":"LI Backus","year":"2014","unstructured":"Backus LI, Belperio PS, Loomis TP, Mole LA. Impact of race\/ethnicity and gender on HCV screening and prevalence among U.S. veterans in Department of Veterans Affairs Care. Am J Public Health 2014;104 Suppl 4:S555\u201361.","journal-title":"Am J Public Health"},{"key":"4649_CR19","doi-asserted-by":"publisher","first-page":"e3719","DOI":"10.1097\/MD.0000000000003719","volume":"95","author":"P Vutien","year":"2016","unstructured":"Vutien P, Hoang J, Brooks L Jr, Nguyen NH, Nguyen MH. Racial disparities in treatment rates for chronic hepatitis c: analysis of a population-based cohort of 73,665 patients in the United States. Medicine (Baltimore) 2016;95:e3719.","journal-title":"Medicine (Baltimore)"},{"key":"4649_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/jvh.12507","volume":"23","author":"O Falade-Nwulia","year":"2016","unstructured":"Falade-Nwulia O, Mehta SH, Lasola J, et al. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. J Viral Hepat 2016;23:366\u201374.","journal-title":"J Viral Hepat"},{"key":"4649_CR21","unstructured":"Ehrlich S. Zuckerberg San Francisco General FY1516 Annual Report2016."},{"key":"4649_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"4649_CR23","doi-asserted-by":"publisher","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.","journal-title":"BMJ"},{"key":"4649_CR24","doi-asserted-by":"publisher","first-page":"e0161241","DOI":"10.1371\/journal.pone.0161241","volume":"11","author":"K Bourgi","year":"2016","unstructured":"Bourgi K, Brar I, Baker-Genaw K. Health disparities in hepatitis c screening and linkage to care at an integrated health system in Southeast Michigan. PLoS One 2016;11:e0161241.","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"4649_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/00333549161310S209","volume":"131","author":"AG Geboy","year":"2016","unstructured":"Geboy AG, Mahajan S, Daly AP, et al. High hepatitis C infection rate among baby boomers in an urban primary care clinic: results from the HepTLC initiative. Public Health Rep 2016;131 Suppl 2:49\u201356.","journal-title":"Public Health Rep"},{"key":"4649_CR26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2105\/AJPH.2016.303163","volume":"106","author":"MJ Akiyama","year":"2016","unstructured":"Akiyama MJ, Kaba F, Rosner Z, Alper H, Holzman RS, MacDonald R. Hepatitis C screening of the \u201cbirth cohort\u201d (Born 1945-1965) and younger inmates of new York City jails. Am J Public Health 2016;106:1276\u20137.","journal-title":"Am J Public Health"},{"key":"4649_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pop.2016.09.013","volume":"44","author":"AA Kowalchuk","year":"2017","unstructured":"Kowalchuk AA, Gonzalez SJ, Zoorob RJ. Substance use issues among the underserved: United States and International Perspectives. Prim Care 2017;44:113\u201325.","journal-title":"Prim Care"},{"key":"4649_CR28","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1007\/s10620-016-4340-x","volume":"61","author":"KR Beck","year":"2016","unstructured":"Beck KR, Kim N, Khalili M. Sofosbuvir-containing regimens for chronic hepatitis C are successful in the safety-net population: a real-world experience. Dig Dis Sci 2016;61:3602\u20138.","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"4649_CR29","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1086\/313842","volume":"30","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30 Suppl 1:S77\u201384.","journal-title":"Clin Infect Dis"},{"key":"4649_CR30","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1007\/s10620-013-2884-6","volume":"58","author":"KC Kin","year":"2013","unstructured":"Kin KC, Lin B, Chaung KT, et al. Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study. Dig Dis Sci 2013;58:3342\u20137.","journal-title":"Dig Dis Sci"},{"issue":"Suppl 2","key":"4649_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/00333549161310S203","volume":"131","author":"RC Patel","year":"2016","unstructured":"Patel RC, Vellozzi C, Smith BD. Results of hepatitis C birth-cohort testing and linkage to care in selected U.S. sites, 2012\u20132014. Public Health Rep 2016;131 Suppl 2:12\u20139.","journal-title":"Public Health Rep"},{"key":"4649_CR32","doi-asserted-by":"crossref","unstructured":"Wong RJ, Campbell B, Liu B, Baden R, Bhuket T. Sub-optimal testing and awareness of HCV and HBV among high risk individuals at an underserved safety-net hospital. J Community Health 2017.","DOI":"10.1007\/s10900-017-0388-6"},{"key":"4649_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1056\/NEJMp1302973","volume":"368","author":"SD Holmberg","year":"2013","unstructured":"Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med 2013;368:1859\u201361.","journal-title":"N Engl J Med"},{"key":"4649_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pop.2016.09.012","volume":"44","author":"M Devine","year":"2017","unstructured":"Devine M, DeCaporale-Ryan L, Lim M, Berenyi J. Psychological issues in medically underserved patients. Prim Care 2017;44:99\u2013112.","journal-title":"Prim Care"},{"key":"4649_CR35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/liv.12150","volume":"33","author":"S Lubega","year":"2013","unstructured":"Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver Int 2013;33:999\u20131007.","journal-title":"Liver Int"},{"key":"4649_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10620-010-1455-3","volume":"56","author":"M Surjadi","year":"2011","unstructured":"Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Formal patient education improves patient knowledge of hepatitis C in vulnerable populations. Dig Dis Sci 2011;56:213\u20139.","journal-title":"Dig Dis Sci"},{"key":"4649_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1097\/MEG.0b013e328326f598","volume":"21","author":"C Giordano","year":"2009","unstructured":"Giordano C, Druyts EF, Garber G, Cooper C. Evaluation of immigration status, race and language barriers on chronic hepatitis C virus infection management and treatment outcomes. Eur J Gastroenterol Hepatol 2009;21:963\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4649_CR38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.drugpo.2017.07.021","volume":"47","author":"BL Norton","year":"2017","unstructured":"Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy 2017;47:196\u2013201.","journal-title":"Int J Drug Policy"},{"key":"4649_CR39","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/hep.28901","volume":"65","author":"F Su","year":"2017","unstructured":"Su F, Green PK, Berry K, Ioannou GN. The association between race\/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017;65:426\u201338.","journal-title":"Hepatology"},{"key":"4649_CR40","doi-asserted-by":"crossref","unstructured":"Roberson JL, Lagasca AM, Kan VL. Comparison of the hepatitis C continua of care between HCV\/HIV co-infected and HCV mono-infected patients in two treatment eras during 2008-2015. AIDS Res Hum Retrovir. 2017.","DOI":"10.1089\/aid.2017.0092"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-018-4649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-018-4649-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-018-4649-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T10:25:47Z","timestamp":1590143147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-018-4649-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4649"],"URL":"https:\/\/doi.org\/10.1007\/s11606-018-4649-6","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University of California San Francisco Committee on Human Research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors do not have any conflicts of interest to report in connection with this manuscript.Dr. Khalili\u2019s full disclosure includes research grant funding (to her institution) from Gilead Sciences Inc., Intercept Pharmaceuticals, and Abbvie, and she has served on the scientific advisory boards of Gilead Sciences Inc., and Intercept Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}